Mohammad Nouri Sharikabad
Papers
1
Total Citations
22
H-Index
1
About
Dr. Mohammad Nouri Sharikabad is a leading researcher in cardiovascular pharmacogenomics, with a primary focus on optimizing anticoagulation therapy through genetic insights. His seminal 2008 study, "Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction," has garnered 22 citations, establishing a foundational link between genetic variations in the warfarin-metabolizing enzyme CYP2C9 and the vitamin K-activating enzyme VKORC1, and individual dosage requirements. This work directly addressed the narrow therapeutic range of warfarin, demonstrating how genotyping can predict patient-specific dosing to minimize bleeding or thrombotic risks. By integrating pharmacogenetics into cardiovascular care, Sharikabad’s contributions have advanced personalized medicine, enabling safer, more effective anticoagulation for myocardial infarction patients. His research underscores the clinical utility of genetic testing in routine practice, a paradigm shift that continues to influence guidelines and inspire further studies on genotype-guided dosing. Through this impactful work, Sharikabad has positioned himself at the forefront of translating genomic discoveries into tangible improvements in patient outcomes.
Research Focus
Key Achievements
Top Papers
- 1